Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC and Toripalimab in MIBC
NCT05016973Phase 2Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2021
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in Muscle Invasive Bladder Cancer (MIBC), sponsored by Nanjing Drum-Tower Hospital. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT05016973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016973.